Form 4 Filing for Acumen Pharmaceuticals, Inc.

Nathan B. Fountain, a director at Acumen Pharmaceuticals, Inc., reported the sale of 6,400 shares of common stock on June 9, 2026. The sales were executed at a weighted average price of $2.2301 per share, with individual transactions ranging from $2.2300 to $2.2311. Following these transactions, Mr. Fountain holds 48,150 shares of common stock. The filing includes a footnote detailing the weighted average price and offering full information regarding specific prices upon request to the SEC, the Issuer, or any security holder. This transaction is classified as a disposition of securities by an insider.